Iterum Therapeutics: Strategic Positioning and Growth Potential with ORLYNVAH Launch

In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Iterum Therapeutics (ITRM – Research Report), with a price target of $9.00.

Matthew Keller has given his Buy rating due to a combination of factors that highlight Iterum Therapeutics’ strategic positioning and potential for growth. The recent Product Commercialization Agreement (PCA) with Eversana Life Science Services is a pivotal step in preparing for the launch of ORLYNVAH, expected in the fourth quarter of 2025. This partnership is set to provide essential sales and commercial operations services, which are crucial for a successful market entry.
Moreover, Iterum’s proactive efforts in outreach and education, optimal pricing strategies, and securing manufacturing resources underscore their commitment to the launch timeline. ORLYNVAH’s unique position as the first orally administered penem antibiotic addresses a significant unmet need in the treatment of urinary tract infections, particularly in the face of rising antibiotic resistance. With robust intellectual property protection and demonstrated clinical superiority, ORLYNVAH is well-positioned to make a substantial impact in the market. These strategic initiatives and the promising market potential underpin Keller’s optimistic outlook and Buy rating for Iterum Therapeutics.